Adalimumab in psoriatic arthritis: 24-week results of a phase III study - 21/08/11
Philip Mease, MD, University of Washington School of Medicine, Seattle, WA, United States; Dafna Gladman, MD, University of Toronto, Toronto, ON, Canada; Christopher Ritchlin, MD, University of Rochester, Rochester, NY, United States; Mark Weinberg, MD, Abbott Laboratories, Abbott Park, IL, United States
Le texte complet de cet article est disponible en PDF. P6 Financial relationships with Abbott Laboratories: Dr. Mease writes research grants, receives consulting fees, and in on the Abbott Laboratories speaker's bureau. Dr. Gladman is a clinical investigator for and it on the advisory board of Abbott Laboratories. Dr. Ritchlin writes research grants for Abbott Laboratories. Dr. Weinberg is employed by Abbott Laboratories. Abbott Laboratories supported this study and the printing of this poster. |
Vol 52 - N° 3S
P. P2 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?